-
Mashup Score: 12Google Forms: Sign-in - 11 day(s) ago
Access Google Forms with a personal Google account or Google Workspace account (for business use).
Source: accounts.google.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5
Whether you’ve had prostate cancer and have been successfully treated for it, or you’re in treatment for advanced disease….don’t forget about the rest of your body! Especially, your heart. Because of their age, gender, other chronic illnesses, and certain treatments, patients with prostate cancer can be at risk of heart disease. The good news is, there’s a lot you can do to power up your heart health, starting with awareness. Zachary Klaassen, MD, MSc, of Wellstar MCG Health hosts a discussion with his colleague, cardio-oncologist Avirup Guha, MBBS, MPH. Learn how you can work with your treatment team to lower your risk and boost your overall wellness. We’ll have a special guest joining to offer nutrition and exercise tips – so stay tuned! Please send questions in advance to webinar@pcf.org. The webinar will be recorded. PCF thanks Lantheus and Veracyte, Inc., our generous Gold Level supporters who make this webinar series possible.
Source: us06web.zoom.usCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 28Editorial Comment on - 7 month(s) ago
We read with interest the recent Urology article from Millot et al.1 assessing major complications and adverse events (AEs) related to SpaceOAR hydrogel for prostate cancer (PCa) radiotherapy. There are several sobering findings in this study of the Manufacturer and User Facility Device Experience (MAUDE) database related to SpaceOAR complications – among 990 reported events, there were 350 (35%) patient injuries, 91 (9%) abscesses and fistulas, 5 (0.5%) mortalities, and 123 (12%) Common Terminology Criteria for Adverse Events (CTCAE) grade 3+ AEs.
Source: www.goldjournal.netCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 182024 American Urological Association (AUA) - 7 month(s) ago
UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Source: www.urotoday.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 182024 American Urological Association (AUA) - 7 month(s) ago
UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Source: www.urotoday.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 43
Adjuvant pembrolizumab therapy after surgery for renal-cell carcinoma was approved on the basis of a significant improvement in disease-free survival in the KEYNOTE-564 trial. Whether the results r…
Source: www.nejm.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 6Sign up - 1 year(s) ago
UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Source: www.urotoday.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2
This cohort study investigates if the introduction of doublet therapy is associated with changes in survival in individuals with de novo metastatic castration-sensitive prostate cancer.
Source: jamanetwork.comCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 0ASCO 2023 - 1 year(s) ago
UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Source: www.urotoday.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 19Prostate Cancer Patient Voices - 2 year(s) ago
Empowering men with the knowledge to navigate their prostate cancer journey.
Source: Prostate Cancer Patient VoicesCategories: Hem/Oncs, Latest HeadlinesTweet
Taking applications for the 2025 GU Early Career Thought Leaders conference in Philadelphia 3/6-3/8, led by @apolo_andrea and myself! Secure your spot for two days of professional development and networking here: https://t.co/cR2YOiS4SD @urotoday @PCFnews @PhillipKooMD